Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B001+SI-B003 Combined With Platinum-based Chemotherapy in HNSCC
NCT06668961Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of izalontamab and SI-B003 in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by Biokin Pharmaceutical. Primary endpoint: Objective Response Rate at 24 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
izalontamabSI-B003
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06668961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668961.